November 2011
Silvie Timmers, Ellen Konings, Lena Bilet, Riekelt H Houtkooper, Tineke van de Weijer, Gijs H Goossens, Joris Hoeks, Sophie van der Krieken, Dongryeol Ryu, Sander Kersten, Esther Moonen-Kornips, Matthijs K C Hesselink, Iris Kunz, Vera B Schrauwen-Hinderling, Ellen Blaak, Johan Auwerx, Patrick Schrauwen
Abstract
Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days.
Resveratrol significantly reduced sleeping and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate.
Furthermore, resveratrol elevated intramyocellular lipid levels and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased.
In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.
